In adult frogs soluble antigen HGG was used to determine humoral anti-HGG antibodies following immunization at day Q (primary treatment) and four weeks after (challenge) and tested for antibodies two, four and six weeks after the challenge. It was found that those frogs, which received only one dose of HGG either as primary treatment or as a challenge, produced low antibody titres when compared with those frogs, which received HGG troth in primary treatment as well as in the challenge. Moreover, use of adjuvant had not significant enhancing affect, rather it decreased the antibody titres when compared with that of the use of antigen in saline.